A 50-year journey in the development of treatment for benign prostatic hyperplasia.

IF 4.1 Q2 GERIATRICS & GERONTOLOGY

npj aging Pub Date : 2025-05-23 DOI:10.1038/s41514-025-00231-2

Andrew V Schally, George Theodoropoulos, Wei Sha, Irving Vidaurre, Medhi Wangpaichitr

{"title":"A 50-year journey in the development of treatment for benign prostatic hyperplasia.","authors":"Andrew V Schally, George Theodoropoulos, Wei Sha, Irving Vidaurre, Medhi Wangpaichitr","doi":"10.1038/s41514-025-00231-2","DOIUrl":null,"url":null,"abstract":"<p><p>Recent research underscores the crucial role of hormone regulation in benign prostatic hyperplasia (BPH) and the therapeutic promise of growth hormone-releasing hormone (GH-RH) antagonists. BPH incidence in aging men doubled over three decades, driven by prostatic enlargement and lower urinary tract symptoms (LUTS). Aging-related changes in GH-RH and luteinizing hormone-releasing hormone (LH-RH) biology promote BPH through hormonal and inflammatory processes. Traditional therapies provide symptomatic relief but often fail to prevent progression. This review explores the 50-year extensive development of LH-RH and GH-RH peptide analogs from discovery to delivery and their potential in BPH treatment. In preclinical studies, GH-RH antagonists reduced prostate volume, improved LUTS, and modulated inflammation mediated by NF-κB and IGF-I. Clinical trials are needed to validate antagonist efficacy and safety. Given BPH's public health impact among the aged, and especially among aging Veterans, integrating GH-RH antagonists into management strategies may offer precision-based therapeutic advancements.</p>","PeriodicalId":94160,"journal":{"name":"npj aging","volume":"11 1","pages":"41"},"PeriodicalIF":4.1000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102307/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj aging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s41514-025-00231-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Recent research underscores the crucial role of hormone regulation in benign prostatic hyperplasia (BPH) and the therapeutic promise of growth hormone-releasing hormone (GH-RH) antagonists. BPH incidence in aging men doubled over three decades, driven by prostatic enlargement and lower urinary tract symptoms (LUTS). Aging-related changes in GH-RH and luteinizing hormone-releasing hormone (LH-RH) biology promote BPH through hormonal and inflammatory processes. Traditional therapies provide symptomatic relief but often fail to prevent progression. This review explores the 50-year extensive development of LH-RH and GH-RH peptide analogs from discovery to delivery and their potential in BPH treatment. In preclinical studies, GH-RH antagonists reduced prostate volume, improved LUTS, and modulated inflammation mediated by NF-κB and IGF-I. Clinical trials are needed to validate antagonist efficacy and safety. Given BPH's public health impact among the aged, and especially among aging Veterans, integrating GH-RH antagonists into management strategies may offer precision-based therapeutic advancements.

查看原文本刊更多论文

良性前列腺增生治疗的50年历程。

最近的研究强调了激素调节在良性前列腺增生（BPH）中的重要作用，以及生长激素释放激素（GH-RH）拮抗剂的治疗前景。前列腺肥大和下尿路症状（LUTS）在老年男性中的发病率在30年内翻了一番。衰老相关的GH-RH和促黄体激素释放激素（LH-RH）生物学变化通过激素和炎症过程促进BPH。传统疗法能缓解症状，但往往不能阻止病情恶化。本文综述了50年来rh - rh和GH-RH肽类似物从发现到递送的广泛发展及其在BPH治疗中的潜力。在临床前研究中，GH-RH拮抗剂可减少前列腺体积，改善LUTS，并调节NF-κB和IGF-I介导的炎症。需要临床试验来验证拮抗剂的有效性和安全性。鉴于BPH对老年人，特别是老年退伍军人的公共卫生影响，将GH-RH拮抗剂纳入管理策略可能会提供基于精准治疗的进步。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

npj aging

CiteScore

8.90

自引率

0.00%

发文量